Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jun 7:6:49-56.
doi: 10.2147/PGPM.S44800. Print 2013.

Molecular targeted therapies in metastatic melanoma

Rima Chakraborty  1 , Carilyn N Wieland, Nneka I Comfere
Affiliations

Molecular targeted therapies in metastatic melanoma

Rima Chakraborty et al. Pharmgenomics Pers Med. .

Abstract

The advent of personalized medicine has ushered in a new era for cancer therapy with a significant impact on the management of advanced melanoma. Molecular targeted therapies have shown promise in the management of various malignancies, including melanoma, with lower toxicity profiles and better overall survival as compared with conventional therapy. The discovery of BRAF mutations in melanoma led to the development of BRAF inhibitors for the treatment of advanced melanoma. However, growing concerns over drug resistance to molecular targeted therapies including BRAF inhibitors, have spurred efforts to elucidate additional molecular targets for the treatment of advanced melanoma. In this review, we discuss the known molecular aberrations in melanoma, current and novel targeted approaches in its treatment, and drug resistance patterns.

Keywords: BRAF inhibitors; metastatic melanoma; personalized medicine.

PubMed Disclaimer

References

    1. National Cancer Institute. A snapshot of melanoma. 2012. Available from: http://www.cancer.gov/researchandfunding/snapshots/pdf/Melanoma-Snapshot.... Accessed January 16, 2013.
    1. National Cancer Institute. SEER Stats Facts sheets. Melanoma of the skin. Available from: http://seer.cancer.gov/statfacts/html/melan.html. Accessed April 16, 2013.
    1. Eggermont AM, Schadendorf D. Melanoma and immunotherapy. Hematol Oncol Clin North Am. 2009;23:547–564. - PubMed
    1. Eggermont AM, Kirkwood JM. Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? Eur J Cancer. 2004;40:1825–1836. - PubMed
    1. Chapman PB, Einhorn LH, Meyers ML, et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol. 1999;17:2745–2751. - PubMed

LinkOut - more resources